{
  "docId": "019de075-7d9e-72c3-b72b-f46b67767727",
  "docSlug": "53c1bfc711678d7524a7d4316a5473e9",
  "documentTitle": "Chimerix | Investor Presentation Deck | 43 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 43,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "The chart is a waterfall plot showing Best % Change in SPD from Baseline. The legend indicates PS scores (060-100).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7d9e-72c3-b72b-f46b67767727/11",
  "deckHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727",
  "deckJsonHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727.json",
  "deckAnchorHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.5,
        "x": 0.45,
        "y": 0.15
      },
      "kind": "chart",
      "text": "ONC201 Ph 2 Efficacy Analysis by BICR in Recurrent H3 K27M-mutant Diffuse Midline Glioma",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b458a48-a4f4-4f0a-a4d8-7546cd59e631",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.04,
        "y": 0.38
      },
      "kind": "paragraph",
      "text": "Predictably, patients with higher PS were more likely to respond to treatment\n100: 1/2 (50%)\n90: 4/14 (29%)\n80: 4/20 (20%)\n70: 1/7 (14%)\n60: 0/7 (0%)\nSupports hypothesis that treating earlier in disease course may enhance efficacy",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d84a038e-d3eb-4bae-9980-ef9e07b953bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.45,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "* Change > 100%, SPD=sum of products of perpendicular diameters (target enhancing lesions per BICR)\nOnly patients with measurable target enhancing lesions at both baseline and post-baseline are included.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2869cbb-ee30-49c5-9f37-f35cf3850ffe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "RANO HGG response correlation to performance status (PS) supports early-line trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "529bbc7e-9d73-4999-a0b7-cdff93163099",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 7,
      "beatId": "ccc4bb10-21c5-4108-a909-a6dcfbb735cf",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The deck presents efficacy data and analysis to agitate the need for better treatment options",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "94af67d1-e80e-42ee-8d7b-9970ecae23e8",
      "evidence": "The deck presents data on the high unmet need and potential benefits of ONC201",
      "position": 0,
      "objective": "What is the cost of not treating H3 K27M-mutant diffuse glioma effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}